文献速递重症综合管理与镇静镇痛消化、代谢与肾脏急症

体成分指导的重症患者蛋白质剂量:PROGRESS-ICU 前后对照研究

Body composition-guided protein dosing in critically ill patients: a before-and-after study (PROGRESS-ICU).
PubMed 文献 · Crit Care · 2026-06-22
一句话结论观察性前后对照研究显示,去脂体重调整的蛋白质剂量与总休重剂量相比90天死亡率无显著差异(校正HR 0.78,95%CI 0.56-1.09),ICU停留和机械通气时间缩短的关联可能受残余混杂影响。

PROGRESS-ICU 为观察性前后对照队列研究,纳入 2020 年 4 月至 2025 年 10 月成人 ICU 患者 620 例(每组 310 例),比较总休重(TBW)指导的蛋白质剂量(1.5 g/kg/天,2020 年 4 月至 2023 年 6 月)与去脂体重(FFM)指导的剂量(干 FFM 1.85 g/kg/天,校正液体过负荷,2023 年 7 月起)。主要终点 90 天全因死亡率两组无显著差异(校正 HR 0.78,95%CI 0.56-1.09)。FFM 组与更短 ICU 停留(HR 0.79,95%CI 0.69-0.91)和更少有创机械通气天数(HR 0.79,95%CI 0.65-0.96)相关,住院时间相似(HR 0.86,95%CI 0.67-1.10);TBW 组尿素/肌酐比值轨迹更高、FFM 丢失更多。作者认为这些关联可能反映残余混杂和时间变化,研究把握度不足以检测死亡率的小幅差异,结果属探索性,需在把握度充足的随机对照试验中确认。

要点

  • 90天全因死亡率:FFM组 vs TBW组校正HR 0.78(95%CI 0.56-1.09),未达统计学显著,置信区间包含临床相关获益或危害的可能。
  • FFM指导的蛋白质剂量与更短ICU停留相关(HR 0.79,95%CI 0.69-0.91),与更少有创机械通气天数相关(HR 0.79,95%CI 0.65-0.96)。
  • 住院时间两组相似(HR 0.86,95%CI 0.67-1.10);TBW组尿素/肌酐比值轨迹更高、FFM丢失更多。
  • TBW队列COVID-19入院比例更高(40% vs 1%),可能影响结果;作者强调观察性设计、基线严重失衡和残余混杂使关联需谨慎解读。
  • 作者结论:FFM指导的蛋白质剂量与TBW指导相比死亡率无差异,研究把握度不足,结果属探索性,需把握度充足的随机对照试验确认。

适用人群与场景

  • 成人ICU患者,纳入时间为2020年4月至2025年10月,均具有连续生物电阻抗分析数据。
  • TBW队列(2020年4月至2023年6月)接受基于总休重的蛋白质剂量;FFM队列(2023年7月起)接受基于去脂体重的蛋白质剂量。
  • TBW队列COVID-19入院比例更高(40% vs 1%),可能影响结果。

处置流程与药物剂量

  • TBW指导的蛋白质剂量:1.5 g/kg/天(2020年4月至2023年6月)。
  • FFM指导的蛋白质剂量:干FFM 1.85 g/kg/天,校正液体过负荷(2023年7月起)。

研究设计与关键结果

  • 研究类型:观察性前后对照队列研究(PROGRESS-ICU),样本量620例(每组310例),单中心未明确报告;人群为成人ICU患者,均具有连续生物电阻抗分析数据。
  • 主要终点:90天全因死亡率两组无显著差异(校正HR 0.78,95%CI 0.56-1.09)。
  • 次要终点:FFM组ICU停留更短(HR 0.79,95%CI 0.69-0.91);有创机械通气天数更少(HR 0.79,95%CI 0.65-0.96);住院时间两组相似(HR 0.86,95%CI 0.67-1.10)。
  • 代谢指标:TBW组尿素/肌酐比值轨迹更高、FFM丢失更多。
  • 基线特征:中位年龄69岁,约60%为男性;TBW队列COVID-19入院比例更高(40% vs 1%)。

证据类型、等级与局限

  • 证据类型:观察性前后对照队列研究。
  • 作者自述局限:观察性设计、基线严重失衡、潜在残余混杂、时间变化可能影响关联;研究把握度不足以检测死亡率的小幅差异,置信区间包含临床相关获益或危害的可能。
  • 作者结论:结果属探索性,需在把握度充足的随机对照试验中确认。

对床旁实践的改变

  • 作者认为,FFM指导的蛋白质剂量与TBW指导相比90天死亡率无差异,但ICU停留和机械通气时间的关联可能反映残余混杂和时间变化,结果属探索性,需随机对照试验确认。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: To compare whether fat-free mass (FFM)-adjusted protein dosing is associated with different clinical and metabolic outcomes compared with total body weight (TBW)-based dosing in critically ill patients in the intensive care unit (ICU).

METHODS: Adult ICU patients (April 2020-October 2025) with serial bioelectrical impedance analysis were included in the PROGRESS-ICU observational cohort study. Patients received either TBW-based protein dosing (1.5 g/kg/day; April 2020-June 2023) or FFM-based dosing after protocol revision (1.85 g/kg/day dry FFM, corrected for fluid overload; July 2023 onward). The primary outcome was 90-day all-cause mortality. Secondary outcomes included 30-day mortality, ICU and hospital length of stay, invasive mechanical ventilation (IMV) duration, and longitudinal changes in FFM and urea-to-creatinine ratio (UCR). Survival was analysed using multivariable Cox regression and inverse probability of treatment weighting; longitudinal outcomes were assessed using mixed-effects models.

RESULTS: Among 620 patients (310 per cohort), median age was 69 years, and ~ 60% were male. Notable baseline differences included a higher proportion of COVID-19 admissions in the TBW cohort (40% vs. 1%), which may have influenced outcomes. Ninety-day mortality did not differ significantly between groups (adjusted hazard ratio [HR] 0.78, 95% CI 0.56-1.09). FFM-based dosing was associated with shorter ICU stay (HR 0.79, 95% CI 0.69-0.91) and fewer IMV days (HR 0.79, 95% CI 0.65-0.96); hospital length of stay was similar (HR 0.86, 95% CI 0.67-1.10). TBW-based dosing was associated with higher UCR trajectories and greater FFM loss. These associations should be interpreted cautiously due to the observational design, substantial baseline imbalances, and potential residual confounding.

CONCLUSIONS: In this observational before-after study, FFM-based protein dosing was not associated with differences in mortality compared with TBW-based dosing. Associations with ICU stay, IMV duration, and metabolic markers were observed but may reflect residual confounding and temporal changes. The study was underpowered to detect modest differences in mortality, and confidence intervals include the possibility of clinically relevant benefit or harm. These findings are exploratory and require confirmation in adequately powered randomised controlled trials.

TRIAL REGISTRATION: The study was approved by the local ethics committee (protocol number 2403-017; 11 April 2024) and registered prior to data analysis on ClinicalTrials.gov (NCT07312708; 5 December 2025), the Open Science Framework ( https://doi.org/10.17605/OSF.IO/3SU49 ; 4 December 2025), and the Dutch Central Committee on Research Involving Human Subjects (NL-010953; 26 October 2025). Patients admitted before ethics approval were retrospectively included under a waiver of informed consent, and from April 2024 an opt-out consent procedure was implemented for all new admissions. Data were collected as part of routine clinical care. The study protocol, including prespecified analyses, was finalised and registered before the research team accessed the data.

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Paulus MC, Hajeer F, van Zanten ARH, et al. Body composition-guided protein dosing in critically ill patients: a before-and-after study (PROGRESS-ICU). Crit Care. 2026. PMID: 42332775. doi:10.1186/s13054-026-06107-5

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。